Alzheimer’s Neurotransmitter Study
Patients with mild to moderate Alzheimer’s disease often have negative changes in how efficiently their bodies process dopamine, a neurotransmitter that helps nerve cells send messages to each other. This can lead to adverse changes in personality, mood, and behavior. This investigational drug enhances the body’s ability to utilize dopamine.
Preliminary Qualifications
-
You are 50-80 years old
-
You have gradual & progressive decline in memory function for more than 6 months.
-
You have historical evidence of Alzheimer's disease